Not terribly impressive given the risk involved, BUT way better than a thumb in the eye ! And vastly better than when we wandered in the wilderness of the terrible twos . Thumbs up !
GILD--- probably not your kind of stock. the potential lottery winner is GNSZ see their presentation on their web site. The drug appears to work and would have wide potential application. At my last check 40% (2 of 5) of the original phase 1 trial are still alive well beyond expectations.
The newly diagnosed type 2 diabetics will far more likely go to metformin and a once a day oral pill (possible side effects be damned) so as to fuss with it only once a day. Yes, Afrezza will find a place , but probably only 3 to five years after initial diagnosis.
As a type 2, I have a quite good handle on how denial works.
As for extending patents : Would not the predecessor drug would still be available, probably in generic form, still doing an adequate job and MUCH cheaper ?
It looks like option players will lose max. money at $7.00 . Both put and call position will be pained.
two other possibilities might be annual flu vaccine and phenomena vaccine. Not often , but important. However, Matese isn't wrong either .
8 thumbs down, it is amazing how threatened people by just a little reality and your expressed concerns are modest compared to the hoops the FDA will likely want jumped through. Never let reality intrude in the discussion!
Nothing wrong with the medication , the deal however ? Time will likely tell us it is an ok deal and at least modestly profitable. In the meantime , people have bills and a lifestyle (or a divorce) to maintain. They also have an expectation of numerous other stock awards over the next few years. Or, perhaps they just know what their stock is worth.
No, for the bulk of that period I been investing in MNKD and still do. I like Afrezza, Al Mann and MNKD not so much.